Late-stage data also showed that Johnson & Johnson’s icotrokinra was superior to Bristol Myers Squibb’s Sotyktu at clearing ...
The reduction in itch was the greatest contributor to quality-of-life improvement for adolescents and adults with atopic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback